# Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa

> **NCT01786395** · PHASE3 · TERMINATED · sponsor: **R-Tech Ueno, Ltd.** · enrollment: 202 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** UF-021
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01786395
- **Lead sponsor:** R-Tech Ueno, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2015-04
- **Final completion:** —
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2016-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01786395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01786395, "Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01786395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*